Selling Tirzepatide: Demand, Margins, and Rules

tirzepatide is the product med spa operators ask us about more than any other right now, and the answer is the same one we give on semaglutide with one commercial difference. structurally it is a prescription drug in the united states — licensed provider, real evaluation, licensed pharmacy, no direct-to-consumer product sale. commercially, it commands more pricing power and more inbound demand than almost anything else in aesthetics. that combination is why it is worth building around and why it is worth building carefully.

this is a business guide, not medical guidance. we are not covering dosing, titration, administration, or clinical protocol. those belong to your licensed providers. nothing here is medical or legal advice.

the demand picture

three things characterize tirzepatide demand from an operator seat. first, it is name-known — prospects search the compound, not the outcome, which means high commercial intent and low education burden. second, it skews toward buyers who have already tried something else, which means they arrive with sophisticated questions and less price sensitivity. third, demand is remarkably durable in the acquisition funnel: it does not have the seasonal collapse that most aesthetic services do.

the operational consequence is that your bottleneck is almost never lead volume. it is provider capacity, intake throughput, pharmacy reliability, and fulfillment. we have seen med spas turn on paid, generate more qualified consults than their provider panel could see in a month, and burn the leads. build the back end to the volume you are about to create.

the rules, plainly

tirzepatide is not available to you as a consumer product. the compliant structures are the same as any prescription program:

1. 1.a provider licensed in the patient's state conducts a genuine evaluation and makes an independent prescribing decision, including the decision to decline
2. 2.a licensed pharmacy dispenses against a valid patient-specific prescription
3. 3.your corporate structure respects corporate practice of medicine rules in every state you operate — MSO and PC arrangements exist for this and must be papered properly
4. 4.telehealth, prescribing, and pharmacy regulations are three separate regimes and all three apply to you simultaneously
5. 5.adverse event capture, escalation, and documentation exists before your first patient

the compounded question specifically: the latitude compounders had during shortage conditions has narrowed, and the distinction between a permissible patient-specific formulation and a copy of a commercially available drug is the thing that determines your exposure. that is a current-guidance question. get an attorney who tracks it and re-check it quarterly. do not build a marketing plan on a legal position you have not verified this quarter.

the research-use-only channel for tirzepatide exists and we tell operators to stay out of it. selling a prescription drug analog into consumer demand under an RUO label is the clearest enforcement and processor-termination fact pattern in this entire category. the margin is real and the business does not survive.

margins: it is a retention business

tirzepatide programs carry good gross margin, but the gross margin is not the interesting number. these are subscription care programs and their economics are decided by month three and month six retention, because your entire acquisition cost lands in month one.

model the full per-patient-month cost stack:

• —product and pharmacy cost per fill
• —provider compensation per encounter, including follow-ups you are not billing separately
• —platform, EHR, and e-prescribing costs per active patient
• —shipping, including any temperature-controlled requirements
• —payment processing at high-risk rates, plus chargeback and refund provisioning
• —support labor, which is higher in month one and two than operators forecast

then compare against blended cac and actual cohort retention. we routinely see programs that show a healthy first-order margin and lose money on the cohort, because unbilled provider time and support load in the early months were never modeled. the fix is usually program design rather than price: fewer, better-structured touchpoints, clearer expectations set at intake, and a support flow that deflects the predictable questions before they become calls.

sourcing and quality expectations

if you are running a compounded program, your pharmacy partner is your quality function and your risk exposure. treat partner selection with the same rigor you would apply to any manufacturing relationship.

1. 1.verify state licensure in every state you ship to, plus any applicable outsourcing facility registration
2. 2.review inspection history and any regulatory correspondence you can obtain
3. 3.require lot-level potency and sterility testing documentation, with the analytical method named
4. 4.understand their beyond-use dating basis and their stability data, not just the number on the label
5. 5.confirm their recall procedure and adverse event handling in writing, and test the communication path once
6. 6.have a second qualified pharmacy relationship live before you need it — single-source dependency in this category is an existential risk

marketing tirzepatide compliantly

the same weight-loss policy constraints apply as with any glp-1 offer: no before-and-after imagery, no pound-count or timeline promises, no copy that assumes something about the viewer's body, and age-restricted targeting. accounts in this category get restricted routinely.

what performs inside the rules is legitimacy content. this market is saturated with offers and the buyer's actual question is whether you are real. answer that: named licensed providers, how the evaluation works, how quickly they get a decision, what happens if they are not approved, where the medication comes from, what the follow-up looks like, and exactly what it costs with no surprise fees. that is compliant, and it is the highest-converting angle we run.

• —process and transparency creative over outcome creative
• —high creative volume for redundancy against rejections — we have run 294 concurrent ads on a single med spa account for this reason
• —landing page claims held tighter than ad claims, since review reads the page
• —state gating in the funnel before payment, not after
• —email and sms as primary retention channels, since paid is rented and can be revoked overnight

in this category, the most persuasive thing you can say is not what the product does. it is proof that your operation is real.

where tirzepatide fits your catalog

tirzepatide is an acquisition and retention engine, not a portfolio. it brings in a monthly-transacting, high-trust patient. the profit expansion comes from what sits alongside it — aesthetic services, memberships, and separately-structured non-prescription product lines. keep the compliance regimes cleanly separated: a prescription program and a research-use-only product line should never share creative, claims language, or checkout flow.